These preliminary data suggest that, if dosed according to rigorous dosimetry studies, 131I-VCN may have the potential to significantly synergize with TMZ in the clinical setting of TMZ resistance (i.e., typically newly diagnosed patients with GBM tumors with unmethylated MGMT promoters). The gene discussed is MGMT; the disease is glioblastoma.